Neurotech Pharmaceuticals, Inc. is a privately held biotech company located in Cumberland, Rhode Island. Neurotech has spent years developing the science, technology, team and manufacturing behind NT-501. As a result of a unique partnership and clear direction, we are focused on bringing a long-term treatment to Macular Telangiectasia (MacTel) patients.  Our team is focused on bringing to market this treatment designed to slow the progression of MacTel and the vision impairments it causes in patients who don't have another treatment option. Our goal is to help these patients sustain their quality of life.

Biotechnology

Neurotech Pharmaceuticals, Inc.

Richard Small

Paul Brannelly

Lovisa Selander

Brett Aguiar

Matthew Fera

Andrew Vitorino Ormonde

Jacob Patterson Esq.

Arne Nystuen

Patricia Davis (Patty)

Terry McCurren

Derek Barnett

Sean K.

Scott Bertolami

The Clinical and Market Access Team at Neurotech Pharmaceuticals, Inc. is responsible for ensuring the clinical efficacy and market availability of the NT-501 treatment for Macular Telangiectasia (MacTel) patients. This includes overseeing clinical trials, managing relationships with healthcare providers and payers, and facilitating patient access to the therapy to improve their quality of life.

Clinical and Market Access Team

Quality Control

Quality and Compliance Team

Clinical and Market Access Team

About

Team members

Other teams at Neurotech Pharmaceuticals, Inc.

Quality Control

Quality and Compliance Team